Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Nicholas Theodosakis, M.D.


University of VirginiaBS05/2008
Yale School of MedicinePhD05/2016
Yale School of MedicineMD05/2017

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Theodosakis N, Yoon J, Young K, Getachew E, Mostaghimi A, Semenov YR. Validation of Case Identification for Melasma Using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision Codes. JAMA Dermatol. 2022 Nov 09. PMID: 36350606; PMCID: PMC9647574.
    Citations:    Fields:    
  2. Young K, Pagan AD, Yoon J, Getachew E, Leung B, Nguyen N, Mostaghimi A, Semenov YR, Theodosakis N. Differences in risk of tetracycline-associated hyperpigmentation between racial and ethnic groups in patients with acne vulgaris: A national US retrospective study. J Am Acad Dermatol. 2022 Oct 10. PMID: 36228939.
    Citations:    Fields:    
  3. Theodosakis N, Yoon J, Young K, Getachew E, Mostaghimi A, Semenov Y. Validation of case identification for hyperpigmentation in the setting of medication use using international classification of diseases coding. J Eur Acad Dermatol Venereol. 2022 12; 36(12):e1001-e1003. PMID: 35789040.
    Citations:    Fields:    
  4. Tiu BC, Zubiri L, Iheke J, Pahalyants V, Theodosakis N, Ugwu-Dike P, Seo J, Tang K, Sise ME, Sullivan R, Naidoo J, Mooradian MJ, Semenov YR, Reynolds KL. Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study. J Immunother Cancer. 2022 06; 10(6). PMID: 35705313; PMCID: PMC9204442.
    Citations:    Fields:    Translation:Humans
  5. Pahalyants V, Murphy WS, Klebanov N, Lu C, Theodosakis N, Klevens MR, Estiri H, Lilly E, Asgari M, Semenov YR. Reply to: "COVID-19 vaccination in IMID patients receiving rituximab: A personalized regimen should be formulated". J Am Acad Dermatol. 2022 07; 87(1):e47-e48. PMID: 35364217; PMCID: PMC8961936.
    Citations:    Fields:    Translation:HumansPHPublic Health
  6. Theodosakis N, Ugwu-Dike P, Pahalyants V, Reynolds K, Semenov Y. Title: Immune-checkpoint inhibitor therapy is underutilized in the US: A multi-institutional cohort analysis. Immunol Lett. 2022 04; 244:43-44. PMID: 34974035.
    Citations:    Fields:    Translation:Humans
  7. Pahalyants V, Murphy WS, Klebanov N, Lu C, Theodosakis N, Klevens RM, Estir H, Lilly E, Asgari M, Semenov YR. Immunosuppressive biologics did not increase the risk of COVID-19 or subsequent mortality: A retrospective matched cohort study from Massachusetts. J Am Acad Dermatol. 2022 01; 86(1):252-255. PMID: 34509536; PMCID: PMC8428982.
    Citations: 2     Fields:    Translation:Humans
  8. Yu Z, Theodosakis N, Cavanaugh-Hussey MW, Nambudiri VE, Huang JT, LaChance AH. Health Policy Education in U.S. Dermatology Residency Programs: A Nationwide Survey of Program Leadership. J Drugs Dermatol. 2021 Sep 01; 20(9):1009-1011. PMID: 34491023.
    Citations:    Fields:    Translation:Humans
  9. Kemény LV, Robinson KC, Hermann AL, Walker DM, Regan S, Yew YW, Lai YC, Theodosakis N, Rivera PD, Ding W, Yang L, Beyer T, Loh YE, Lo JA, van der Sande AAJ, Sarnie W, Kotler D, Hsiao JJ, Su MY, Kato S, Kotler J, Bilbo SD, Chopra V, Salomon MP, Shen S, Hoon DSB, Asgari MM, Wakeman SE, Nestler EJ, Fisher DE. Vitamin D deficiency exacerbates UV/endorphin and opioid addiction. Sci Adv. 2021 06; 7(24). PMID: 34117054; PMCID: PMC8195487.
    Citations: 4     Fields:    Translation:HumansAnimals
  10. Klebanov N, Pahalyants V, Murphy WS, Theodosakis N, Zubiri L, Klevens RM, Kwatra SG, Lilly E, Reynolds KL, Semenov YR. Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors. Oncologist. 2021 05; 26(5):e898-e901. PMID: 33783099; PMCID: PMC8100539.
    Citations: 6     Fields:    Translation:HumansCells
  11. Robinson KC, Kemény LV, Fell GL, Hermann AL, Allouche J, Ding W, Yekkirala A, Hsiao JJ, Su MY, Theodosakis N, Kozak G, Takeuchi Y, Shen S, Berenyi A, Mao J, Woolf CJ, Fisher DE. Reduced MC4R signaling alters nociceptive thresholds associated with red hair. Sci Adv. 2021 04; 7(14). PMID: 33811065.
    Citations: 2     Fields:    Translation:Animals
  12. Theodosakis N, Pagan AD, Fisher DE. The role of MiT/TFE family members in autophagy regulation. Curr Top Biochem Res. 2021; 22:151-159. PMID: 35663368; PMCID: PMC9165699.
  13. Yu Z, Theodosakis N, Fitzpatrick MJ, Foreman RK, Mackool B. A 39-Year-Old Male Congenital Tricuspid Atresia Patient Who Presented with a New Axillary Lesion after an Orthotopic Heart Transplant. Dermatopathology (Basel). 2019 Oct-Dec; 6(4):220-224. PMID: 31828063; PMCID: PMC6902244.
    Citations: 1     
  14. Theodosakis N, Langdon CG, Micevic G, Krykbaeva I, Means RE, Stern DF, Bosenberg MW. Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment-resistant melanoma, colorectal, and lung cancer. Pigment Cell Melanoma Res. 2019 03; 32(2):292-302. PMID: 30281931.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  15. Theodosakis N, Micevic G, Langdon CG, Ventura A, Means R, Stern DF, Bosenberg MW. p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis. J Invest Dermatol. 2017 10; 137(10):2187-2196. PMID: 28599981; PMCID: PMC6342201.
    Citations: 11     Fields:    Translation:HumansCells
  16. Micevic G, Theodosakis N, Bosenberg M. Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities. Clin Epigenetics. 2017; 9:34. PMID: 28396701.
    Citations: 59     Fields:    Translation:HumansCells
  17. Micevic G, Theodosakis N, Taube JM, Bosenberg MW, Rodic N. Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas. Melanoma Res. 2017 04; 27(2):85-96. PMID: 27997431; PMCID: PMC5812886.
    Citations: 3     Fields:    Translation:HumansCells
  18. Criscione SW, Theodosakis N, Micevic G, Cornish TC, Burns KH, Neretti N, Rodic N. Genome-wide characterization of human L1 antisense promoter-driven transcripts. BMC Genomics. 2016 06 14; 17:463. PMID: 27301971.
    Citations: 23     Fields:    Translation:HumansAnimalsCells
  19. Theodosakis N, Micevic G, Bosenberg MW, Rodic N. Cell and Tissue Display: An Alternative Multipurpose Tool for Microscopy. J Histochem Cytochem. 2016 07; 64(7):403-11. PMID: 27270967; PMCID: PMC4931762.
    Citations:    Fields:    Translation:HumansAnimalsCells
  20. Theodosakis N, Levy L, Cowper S, Lazova R, Kugelman L, Zubek A, Choate K. Somatic Mosaicism in Blaschkolinear Inflammatory Disorders. J Clin Exp Dermatol Res. 2016; 7(4). PMID: 36267522; PMCID: PMC9581078.
  21. Theodosakis N, Micevic G, Sharma R, Baras AS, Lazova R, Bosenberg MW, Rodic N. Integrative discovery of CD98 as a melanoma biomarker. Pigment Cell Melanoma Res. 2016 May; 29(3):385-7. PMID: 26850337.
    Citations: 2     Fields:    Translation:Humans
  22. Micevic G, Muthusamy V, Damsky W, Theodosakis N, Liu X, Meeth K, Wingrove E, Santhanakrishnan M, Bosenberg M. DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR. Cell Rep. 2016 Mar 08; 14(9):2180-2192. PMID: 26923591; PMCID: PMC4785087.
    Citations: 30     Fields:    Translation:HumansAnimalsCells
  23. Langdon CG, Wiedemann N, Held MA, Mamillapalli R, Iyidogan P, Theodosakis N, Platt JT, Levy F, Vuagniaux G, Wang S, Bosenberg MW, Stern DF. SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells. Oncotarget. 2015 Nov 10; 6(35):37410-25. PMID: 26485762; PMCID: PMC4741938.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  24. Marzuka A, Huang L, Theodosakis N, Bosenberg M. Melanoma Treatments: Advances and Mechanisms. J Cell Physiol. 2015 Nov; 230(11):2626-33. PMID: 25899612.
    Citations: 21     Fields:    Translation:HumansCells
  25. Theodosakis N, Held MA, Marzuka-Alcala A, Meeth KM, Micevic G, Long GV, Scolyer RA, Stern DF, Bosenberg MW. BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume. Mol Cancer Ther. 2015 Jul; 14(7):1680-92. PMID: 25948295; PMCID: PMC4497841.
    Citations: 13     Fields:    Translation:Humans
  26. Damsky W, Micevic G, Meeth K, Muthusamy V, Curley DP, Santhanakrishnan M, Erdelyi I, Platt JT, Huang L, Theodosakis N, Zaidi MR, Tighe S, Davies MA, Dankort D, McMahon M, Merlino G, Bardeesy N, Bosenberg M. mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation. Cancer Cell. 2015 Jan 12; 27(1):41-56. PMID: 25584893; PMCID: PMC4295062.
    Citations: 56     Fields:    Translation:HumansAnimalsCells
  27. Theodosakis N, Micevic G, Kelly DP, Bosenberg M. Mitochondrial function in melanoma. Arch Biochem Biophys. 2014 Dec 01; 563:56-9. PMID: 24997363.
    Citations: 13     Fields:    Translation:HumansAnimalsCells
  28. Damsky WE, Theodosakis N, Bosenberg M. Melanoma metastasis: new concepts and evolving paradigms. Oncogene. 2014 May 08; 33(19):2413-22. PMID: 23728340.
    Citations: 48     Fields:    Translation:HumansAnimals
  29. Taylor MD, Nagji AS, Bhamidipati CM, Theodosakis N, Kozower BD, Lau CL, Jones DR. Tumor recurrence after complete resection for non-small cell lung cancer. Ann Thorac Surg. 2012 Jun; 93(6):1813-20; discussion 1820-1. PMID: 22542070.
    Citations: 59     Fields:    Translation:HumansCells
  30. Taylor MD, Liu Y, Nagji AS, Theodosakis N, Jones DR. Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells. J Thorac Cardiovasc Surg. 2010 May; 139(5):1224-32, 1232.e1. PMID: 20412959; PMCID: PMC4219566.
    Citations: 12     Fields:    Translation:HumansCells
  31. Taylor MD, Smith PW, Brix WK, Wick MR, Theodosakis N, Swenson BR, Kozower BD, Jones DR. Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer. Eur J Cardiothorac Surg. 2009 Apr; 35(4):699-705. PMID: 19136271.
    Citations: 11     Fields:    Translation:Humans
  32. Taylor MD, Smith PW, Brix WK, Wick MR, Theodosakis N, Swenson BR, Kozower BD, Lau CL, Jones DR. Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009 Jan; 137(1):43-8. PMID: 19154901; PMCID: PMC3632077.
    Citations: 11     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Theodosakis's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (177)
Co-Authors (28)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.